The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $35.00 expecting DNLI to rise to within 12 months (a possible 13.23% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by Cantor Fitzgerald, and Denali Therapeutics reiterated their overweight rating.

There is no last upgrade for Denali Therapeutics

There is no last downgrade for Denali Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a reiterated with a price target of $35.00 to $35.00. The current price Denali Therapeutics (DNLI) is trading at is $30.91, which is out of the analyst’s predicted range.